hengrui glp-1 💊 ORAL UPDATE 💊 Kailera/Hengrui's HRS-7535 showed 9.8% weight loss in a 44-week Phase 3 trial in China. 🇨🇳 While effective and free of hepatotoxicity, high rates of nausea (70%) and Jiangsu and Kailera report positive

Does weight loss in overweight or obese women improve fertility treatment outcomes

These effects explain why patients often experience reduced cravings and a natural decline in caloric intake

This is the trial a regulator needs to see before broad cardiovascular labeling

doi: 10.2337/dc12-2454 217 ReuschJStewartMWPerkinsCMCirkelDTYeJPerryCRet al

You will be eligible for a refill when you have about 2-3 weeks of medication remaining

All FDA-approved GLP-1 medications carry important safety information, including contraindications for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)